BCL2 and neoplasm: Such resensitization of treatment resistant tissues, is particularly attributed to the ability of PDT to directly target and inactivate anti-apoptotic proteins (Bcl-2 and Bcl-xL), often over-expressed in treatment resistant tumor cells.